Shares of Allergan plc (NYSE:AGN) have received an average rating of “Hold” from the twenty-three ratings firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $228.69.
Several research firms have recently commented on AGN. Argus lowered shares of Allergan from a “buy” rating to a “hold” rating and reduced their price target for the company from $256.80 to $160.07 in a report on Thursday, December 7th. JPMorgan Chase & Co. set a $275.00 price target on shares of Allergan and gave the company a “buy” rating in a report on Sunday, October 22nd. Morgan Stanley lowered shares of Allergan from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $284.00 to $228.00 in a report on Wednesday, September 20th. Zacks Investment Research lowered shares of Allergan from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Finally, Vetr lowered shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 price target for the company. in a report on Wednesday, December 6th.
In related news, insider William Meury sold 11,807 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher J. Coughlin acquired 10,000 shares of Allergan stock in a transaction that occurred on Tuesday, December 5th. The shares were purchased at an average price of $163.30 per share, with a total value of $1,633,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 17,630 shares of company stock valued at $2,890,057. 0.36% of the stock is currently owned by company insiders.
Shares of Allergan (AGN) opened at $170.56 on Tuesday. The stock has a market cap of $57,300.00, a PE ratio of -7.55, a price-to-earnings-growth ratio of 1.18 and a beta of 1.11. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08. Allergan has a 52-week low of $160.07 and a 52-week high of $256.80.
Allergan (NYSE:AGN) last released its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.06 by $0.09. The company had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.32 EPS. equities research analysts anticipate that Allergan will post 16.27 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Friday, November 17th were paid a dividend of $0.70 per share. The ex-dividend date was Thursday, November 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.64%. Allergan’s dividend payout ratio (DPR) is presently -12.39%.
Allergan declared that its board has approved a stock repurchase program on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.
ILLEGAL ACTIVITY WARNING: “Allergan plc (AGN) Given Consensus Rating of “Hold” by Analysts” was published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/allergan-plc-agn-given-consensus-rating-of-hold-by-analysts/1819826.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.